慢性淋巴细胞白血病 (CLL) 的心血管挑战 接受布鲁顿氨酸激酶 (BTK) 抑制剂治疗的患者
Stefano Oliva1, Stefano Molica2
1Cardio-Oncology Unit, IRCCS Istituto Tumori, "Giovanni Paolo II", Bari, Italy.
慢性淋巴细胞白血病 (CLL) 的布鲁顿氨酸激酶抑制剂 (BTKis) 可以导致心血管 (CV) 问题. 优先考虑第二代BTKis和持续的CV监测有助于管理这些风险并防止治疗中断.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 布鲁顿氨酸激酶抑制剂 (BTKis) 已经改变了慢性淋巴细胞白血病 (CLL) 的治疗方法.
- 心血管 (CV) 毒性是与BTKi治疗相关的重大挑战.
- 第二代BTKis的特异性有所提高,但CV风险仍然存在.
研究的目的:
- 审查有关BTKi相关的CV事件的当前证据.
- 在BTKis上为CLL患者的心血管毒性管理提供指导.
- 为了应对伴随疾病患者的CV风险.
主要方法:
- 由血液学和心脏学专家进行的系统性文献综述.
- 多学科专家讨论以综合发现.
- 制定CV风险分层和管理的实际建议.
主要成果:
- 定期的心血管监测对于检测心房动,高血压和心室节律失常至关重要.
- 建议采用涉及血液学家和心脏病学家的多学科方法.
- 优先确定心脏毒性生物标志物和心脏保护疗法至关重要.
结论:
- 医疗保健提供者必须对与BTKi相关的CV风险进行教育.
- 临床指南需要定期更新以纳入新的证据.
- 优先考虑第二代BTKis和持续的CV监测可以减轻不良事件和停止治疗.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chronic Kidney Disease II: Clinical Manifestations
Cardiomyopathy VI: Nursing Management
Cardiomyopathy V: Interprofessional Care
